On July 15, 2026, a Phase IIb site went live at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based treatment candidate targeting Tourette Syndrome in adults. The sponsor is NeuroThera Labs, a subsidiary of SciSparc Ltd. The activation is quiet news to most. For anyone watching the cannabinoid CNS pipeline, it is a signal worth decoding.
The underlying Phase IIa data, generated at Yale University, showed an average tic reduction of 21% on the Yale Global Tic Severity Scale Total Tic Score across all participants. That is a modest top-line number. But the distribution tells a more interesting story: nearly 40% of patients experienced a tic reduction greater than 25%, with a clean safety profile and no concerning adverse events. That responder subgroup is where Phase IIb will either validate a target population or collapse the hypothesis entirely.
The choice to activate in Germany rather than expand the U.S. site footprint first deserves attention.
The Site Selection Signal
Hannover Medical School carries specific operational weight in CNS neuropsychiatric research. Its activation for a cannabinoid-based adult Tourette program reflects a broader structural reality: European academic medical centers have accumulated meaningful experience with cannabis-derived investigational compounds under national compassionate-use and early-access frameworks that predate U.S. Schedule I research pathways. For a small-cap sponsor like SciSparc, that infrastructure reduces site initiation friction considerably compared to opening a new IND-dependent site in a U.S. state without an established cannabinoid neurology program.
The Tourette Syndrome treatment market itself provides context for why this matters. The market is projected to reach USD 2.85 billion in 2026, growing at a CAGR of 5.06% through 2031, driven primarily by VMAT-2 inhibitor adoption and expanding behavioral therapy coverage. But that growth is largely pediatric-dominated. The adult Tourette population remains underserved by approved pharmacotherapy, which creates both a patient recruitment rationale and a regulatory positioning opportunity for SCI-110, which is targeting adults specifically.
Four medications currently carry FDA approval for tic management, and none were developed with the adult Tourette phenotype as the primary indication. SCI-110 is not entering a crowded field at its target demographic.
The Competitive Clock Is Running
That clear lane will not stay clear. Ecopipam, a first-in-class dopamine D1 receptor antagonist developed by Emalex Biosciences, posted positive Phase III results and is targeting FDA approval and commercial launch in 2026, primarily in the pediatric segment. Ecopipam’s success in Phase III demonstrates that novel mechanism trials in Tourette Syndrome can clear regulatory review, which is useful precedent for SCI-110’s IND strategy. But it also compresses NeuroThera’s window to generate Phase IIb data before payers and prescribers begin anchoring their mental models around a new standard of care.
For clinical operations teams, the Phase IIb design choices made right now will define whether SCI-110 can generate data fast enough to remain competitively relevant. The Yale Phase IIa responder profile, that 40% of patients exceeding 25% tic reduction, argues for an enriched enrollment strategy: pre-screen for baseline tic severity, identify phenotypic responder characteristics from Phase IIa, and power the Phase IIb primary endpoint around that subgroup rather than the full ITT population. If NeuroThera enrolled broadly in Phase IIa and only 40% responded robustly, a precision enrollment strategy in Phase IIb could dramatically improve the probability of a statistically meaningful readout without requiring a massive sample size expansion.
Single-site activation at Hannover introduces its own risk calculus. Phase IIb programs in CNS neuropsychiatric indications routinely underestimate the recruitment burden created by adult Tourette diagnostic heterogeneity: co-occurring OCD, ADHD, and anxiety disorders complicate eligibility screening and inflate screen failure rates. A single academic center, even a capable one, carries real throughput constraints. The enrollment timeline will be the first operational stress test for this program.
What Operations Leaders Need to Watch
If you are managing a CNS Phase II program with a cannabinoid or novel mechanism asset, the SCI-110 Hannover activation raises a direct operational question about your own site selection logic. European academic sites with established neuropsychiatry and movement disorder programs offer lower IND-friction and faster IRB-equivalent approval timelines for cannabinoid compounds, but they also introduce ICH E6(R3) compliance considerations for remote monitoring and data management that differ from purely U.S.-based trials. The EU Clinical Trials Regulation (CTR), which governs trials submitted through the Clinical Trials Information System (CTIS), has specific requirements for protocol transparency and lay summary publication that some small sponsors have found operationally burdensome. NeuroThera’s teams at Hannover will need to be running both CTIS-compliant documentation and sponsor IND-aligned data collection simultaneously if U.S. label ambitions remain on the table.
The 21% average tic reduction from Phase IIa is the number that will appear in every investor deck. The operational question is whether Phase IIb is designed to exceed it at a statistically powered level, or to identify the population for whom SCI-110 reliably delivers the 25%-plus response that already showed up in four out of ten patients at Yale.
Watch for NeuroThera’s additional site announcements over the next 90 days. A second site activation, particularly in a U.S. academic movement disorder center, would signal that the Phase IIb enrollment strategy is built for speed and competitive positioning. A Hannover-only posture through Q4 2026 would suggest the program is prioritizing data quality and regulatory de-risking over timeline, which is a defensible strategy but one that leaves the adult Tourette market increasingly exposed to ecopipam’s commercial momentum and whatever Phase II readouts emerge from the broader pipeline tracked by DelveInsight’s 2024-2026 Tourette pipeline analysis. The next signal to decode is not the science. It is the site map.
References
- GlobeNewswire / SciSparc — “NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome”
- StockTitan / SciSparc — SCI-110 Phase IIa results: 21% average tic reduction, 40% responder rate on YGTSS-TTS; Phase IIb site initiation details
- TheNewsWire — “NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School”
- Mordor Intelligence — “Tourette Syndrome Treatment Market Size and Forecast 2026–2031”
- DelveInsight — “Gilles de la Tourette’s Syndrome Pipeline Insight 2024–2026: Ecopipam Phase III and Competitive Landscape”
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
![Stack of documents clipped with a black binder clip on a wooden desk, with a pen and glasses nearby in sunlight] ,](https://www.clinicaltrialvanguard.com/wp-content/uploads/2026/07/your-recruitment-plan-is-failing-before-screening-even-start-150x150.png)
